Cangene Corporation

Presenter: John Langstaff, President and CEO

Company Information

Company Type: Therapeutics

Development Stage: Public

Company Profile

Led by our experienced senior management team, Cangene posted record revenues and record profits in 2009 an impressive feat given the challenging economic climate.

Recognizing the extraordinary power of antibodies and the immune system, Cangene has been developing, manufacturing and selling hyperimmune therapeutics for nearly thirty years. Most recently, our new products have been aimed at infectious disease and biodefence targets such as hepatitis B, botulism and anthrax. We have five products that have been approved in the United States and/or Canada, and three of our products have been accepted into the U.S. Strategic National Stockpile.

Our business is divided into two operating segments. The core commercial biopharmaceutical product segment provides revenue from approved product sales. The contract-services business is dominated by large government biodefence contracts and generates a somewhat uneven revenue stream that nevertheless adds significant upside as product is delivered.

Cangene has been listed on the Toronto Stock Exchange since 1991 under the symbol CNJ. We have operations in Manitoba and Ontario in Canada, and in California, Maryland and Florida in the United States. The majority of our 700 employees work in Winnipeg or at Cangene bioPharma, Inc., our subsidiary in Baltimore. Additional company information can be found at www.cangene.com and www.cblinc.com.

Management Team

Dr. John Langstaff, President and CEO
William Bees, Senior VP Operations
Paul Brisebois, VP Commercial Development
Michael Graham, CFO
Grant McClarty, VP Research & Development
Francis St. Hilaire,General Counsel & Secretary
Andrew Storey, VP QA/Clinical and Regulatory Affairs

Presenter Bio

JOHN LANGSTAFF, PhD

Dr. John Langstaff has more than twenty years of experience in the business of biopharmaceuticals. He became President and CEO of Cangene Corporation on November 1, 1995 when it amalgamated with Winnipeg-based Rh Pharmaceuticals Inc., a company in which he had been Research Director, Vice President Research and Operations, and President and CEO. He has a PhD in Microbiology from the University of Manitoba. Under his direction, Cangene has been recognized as one of Canada's best employers, one of Canada's fastest growing companies, and as one of the world's top 100 biotechnology companies

Dr. Langstaff is actively committed to the development of science and the healthcare industry in Canada. As well as memberships in various industry organizations, and government healthcare and business committees, he's a past chair of BioNet (a national biotechnology organization), the founder of the Healthcare Products Association of Manitoba, and was co-chair of the Science and Technology Committee for the Economic Innovation and Technology Council of Manitoba. He has also been recognized as a distinguished alumnus by the University of Winnipeg.

Contact

Cangene Corporation
155 Innovation Drive
Winnipeg
MB, Canada
R3T 5Y3

ph: 204-275-4201
fx: 204-269-7003

www.cangene.com
jlangstaff@cangene.com